Literature DB >> 3104215

Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes.

B Holzmann, E B Bröcker, J M Lehmann, D J Ruiter, C Sorg, G Riethmüller, J P Johnson.   

Abstract

The antigenic profile of melanocytic cells in the course of local and systemic tumor progression of human malignant melanoma was investigated by the reactivity of a panel of monoclonal antibodies (MAbs) in frozen sections of histologically defined melanocytic lesions. Specific antigenic phenotypes made it possible to distinguish 5 groups of lesions which could be ranked in relation to each other due to the sequential acquisition or loss of progression markers. On this basis, a scheme of antigenic changes which accompany the stepwise transformation of normal skin melanocytes into highly malignant metastatic melanoma cells is proposed. The steps of tumor progression identified solely by phenotyping with MAbs were in complete concordance with the concept of melanoma progression derived from histological, statistical and clinical analyses. Furthermore, our finding that the expression of gp89 as well as HLA-DR antigens can be induced by interferon-gamma in vitro provides evidence that immune interferon may play a role in the regulation of genes leading to phenotypic changes in progressing melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104215     DOI: 10.1002/ijc.2910390410

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice.

Authors:  G N Van Muijen; L M Cornelissen; C F Jansen; C G Figdor; J P Johnson; E B Bröcker; D J Ruiter
Journal:  Clin Exp Metastasis       Date:  1991 May-Jun       Impact factor: 5.150

Review 2.  Human cutaneous malignant melanoma as a model for cancer.

Authors:  W H Clark
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 3.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

4.  Individual epitopes of an 85,000 MW membrane adherence molecule are variably expressed on cells of different lineage.

Authors:  T F Schulz; W Vogetseder; M Mitterer; G Böck; J P Johnson; M P Dierich
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

5.  DNA content and MHC class II antigen expression in malignant melanoma: clinical course.

Authors:  J Zaloudik; M Moore; A K Ghosh; Z Mechl; A Rejthar
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

6.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

7.  Monoclonal antibodies against a human gastric cancer cell line with lung metastatic potential in nude mice define antigens with different expression between the primary and metastatic liver lesions.

Authors:  S Hokita; S Takao; T Muramatsu; H Shimazu
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype.

Authors:  H Kobayashi; S Man; J R MacDougall; C H Graham; C Lu; R S Kerbel
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

9.  Macrophages in melanocytic naevi.

Authors:  E B Bröcker; C Reckenfeld; H Hamm; D J Ruiter; C Sorg
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

10.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.